Please assess the completion status of the following clinical trial:

Trial Title: Phase II Artesunate Study in Severe Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female children aged 6 months and ≥ 5kg to 10 years, inclusive.~* Clinical diagnosis of severe P. falciparum malaria (see Appendix B) requiring hospitalization.~* Parasitemia (more than 5,000 parasites/microL on initial blood smear).~* Availability of child's parent/guardian and their willingness to provide written informed consent in accordance to local practice.~* Willingness and ability to comply with the study protocol for the duration of the study.~* Willingness to remain in the hospital for 4 days~Exclusion Criteria:~* Known serious adverse reaction or hypersensitivity to artemisinins, including artesunate, artemether, dihydroartemisinins or Co-Artem (artemether/lumefantrine).~* Any underlying disease that may compromise the diagnosis and the evaluation of the response to the study medication (including concomitant infection, concomitant neurological disease and malnutrition)~* Participation in any investigational drug study during the 30 days prior to Screening.~* Adequate anti-malarial treatment within 24 hours prior to admission.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- cohort 1 (Type: ACTIVE_COMPARATOR): 2.4 mg/kg iv artesunate at 0, 12, 24, 48and 72 hours
- cohort 2 (Type: EXPERIMENTAL): 4.0 mg/kg iv Artesunate at 0, 24 and 48 h

Based on this trial design, predict the completion outcome and termination type (if applicable).